Effects of cromolyn sodium on lung function in asthmatic patients

Effects of sodium cromoglycate on lung function tests in asthmitc subejects without exposure to any bronchoconstrictor trigger

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT138804222118N1

Enrollment

120

Registered

2011-07-10

Start date

2011-06-02

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bronchial asthma. Predominantly allergic asthma

Interventions

Intervention 1: 1. cromolyn 20 group: Patient must inhale powder content of a capsule of cromolyn sodium (20 mg) by spinhaler through mouth. Intervention 2: 2. cromolyn 40 group: Patient must inhale

Treatment - Drugs

1. cromolyn 20 group: Patient must inhale powder content of a capsule of cromolyn sodium (20 mg) by spinhaler through mouth.

2. cromolyn 40 group: Patient must inhale 40mg powder of cromolyn sodium by spinhaler through mouth.

3. placebo group:Patient must inhale from a hollow and cleaned (dose not contain any drug) capsule of cromolyn sodium by spinhaler through mouth.

Eligibility

Sex/Gender

All

Age

27 Years to 57 Years

Inclusion criteria

Inclusion criteria: Inclusion critreia: subjects with documented diagnosis of asthma and reversible airflow obstruction; FEV1<80% of predicted value;in a stable condition with regard to asthma symptoms Exclusion criteria: acute attack of asthma; chronic disease such as heart disease; pateints with respiratory infection in last month; smoking

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
FEV1. Timepoint: 15 min, 30 min, 60min after inhalation. Method of measurement: Spirometry test.;FVC. Timepoint: 15min, 30min, 60min after inhalation. Method of measurement: spirometry test.;PEF. Timepoint: 15 min, 30 min, 60min after inhalation. Method of measurement: Spirometry test.;MEF25%. Timepoint: 15 min, 30 min, 60min after inhalation. Method of measurement: Spirometry test.;MEF50%. Timepoint: 15 min, 30 min, 60min after inhalation. Method of measurement: Spirometry test.;MEF75%. Timepoint: 15 min, 30 min, 60min after inhalation. Method of measurement: Spirometry test.	—

Measure

Time frame

FEV1. Timepoint: 15 min, 30 min, 60min after inhalation. Method of measurement: Spirometry test.;FVC. Timepoint: 15min, 30min, 60min after inhalation. Method of measurement: spirometry test.;PEF. Timepoint: 15 min, 30 min, 60min after inhalation. Method of measurement: Spirometry test.;MEF25%. Timepoint: 15 min, 30 min, 60min after inhalation. Method of measurement: Spirometry test.;MEF50%. Timepoint: 15 min, 30 min, 60min after inhalation. Method of measurement: Spirometry test.;MEF75%. Timepoint: 15 min, 30 min, 60min after inhalation. Method of measurement: Spirometry test.

—

Secondary

Measure	Time frame
Adverse effects after inhalation of drug or placebo. Timepoint: each 15 min after inhalation, until 2 hours. Method of measurement: observation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDR TAJEMAH MOMBEINI

SCHOOL OF MEDICINE, SHAHED UNIVERSITY

t.mombeini@gmail.com+98 21 8896 4792

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026